Helen E Dinkelspiel1, Miriam Champer1, June Hou2, Ana Tergas2, William M Burke1, Yongmei Huang1, Alfred I Neugut3, Cande V Ananth4, Dawn L Hershman3, Jason D Wright5. 1. Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, United States. 2. Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, United States; Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, United States; New York Presbyterian Hospital, United States. 3. Department of Medicine, Columbia University College of Physicians and Surgeons, United States; Department of Epidemiology, Mailman School of Public Health, Columbia University, United States; Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, United States; New York Presbyterian Hospital, United States. 4. Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, United States; Department of Epidemiology, Mailman School of Public Health, Columbia University, United States. 5. Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, United States; Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, United States; New York Presbyterian Hospital, United States. Electronic address: jw2459@columbia.edu.
Abstract
OBJECTIVES: Patients with solid tumors are at greatest risk for dying from their cancers in the five years following diagnosis. For most malignancies, deaths from other chronic diseases begin to exceed those from cancer at some point. As little is known about the causes of death among long-term survivors of ovarian cancer, we examined causes of death by years from diagnosis. METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was used to identify women diagnosed with ovarian cancer between 1988 and 2012. We compared causes of death by stage, age, and interval time after diagnosis. RESULTS: A total of 67,385 women were identified. For stage I neoplasms, 13.6% (CI, 13.0-14.2%) died from ovarian cancer, 4.2% (CI, 3.8-4.5%) from cardiovascular disease, 3.6% (CI, 3.3-3.9%) from other causes and 2.6% (CI, 2.4-2.9%) from other tumors; ovarian cancer was the leading cause of death until 7 years after diagnosis after which time deaths are more frequently due to other causes. For those with stage III-IV tumors, 67.8% (CI, 67.3-68.2%) died from ovarian cancer, 2.8% (CI, 2.6-2.9%) from other causes, 2.3% (CI, 2.2-2.4%) from cardiovascular disease and 1.9% (CI, 1.7-2.0%) from other cancers; ovarian cancer was the most frequent cause of death in years 1-15 after which time deaths were more commonly due to other causes. CONCLUSIONS: The probability of dying from ovarian cancer decreases with time. Ovarian cancer remains the most common cause of death for 15 years after diagnosis in women with stage III-IV tumors.
OBJECTIVES:Patients with solid tumors are at greatest risk for dying from their cancers in the five years following diagnosis. For most malignancies, deaths from other chronic diseases begin to exceed those from cancer at some point. As little is known about the causes of death among long-term survivors of ovarian cancer, we examined causes of death by years from diagnosis. METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was used to identify women diagnosed with ovarian cancer between 1988 and 2012. We compared causes of death by stage, age, and interval time after diagnosis. RESULTS: A total of 67,385 women were identified. For stage I neoplasms, 13.6% (CI, 13.0-14.2%) died from ovarian cancer, 4.2% (CI, 3.8-4.5%) from cardiovascular disease, 3.6% (CI, 3.3-3.9%) from other causes and 2.6% (CI, 2.4-2.9%) from other tumors; ovarian cancer was the leading cause of death until 7 years after diagnosis after which time deaths are more frequently due to other causes. For those with stage III-IV tumors, 67.8% (CI, 67.3-68.2%) died from ovarian cancer, 2.8% (CI, 2.6-2.9%) from other causes, 2.3% (CI, 2.2-2.4%) from cardiovascular disease and 1.9% (CI, 1.7-2.0%) from other cancers; ovarian cancer was the most frequent cause of death in years 1-15 after which time deaths were more commonly due to other causes. CONCLUSIONS: The probability of dying from ovarian cancer decreases with time. Ovarian cancer remains the most common cause of death for 15 years after diagnosis in women with stage III-IV tumors.
Authors: A P M Heintz; F Odicino; P Maisonneuve; M A Quinn; J L Benedet; W T Creasman; H Y S Ngan; S Pecorelli; U Beller Journal: Int J Gynaecol Obstet Date: 2006-11 Impact factor: 3.561
Authors: Michelle L Kurta; Robert P Edwards; Kirsten B Moysich; Kathleen McDonough; Marnie Bertolet; Joel L Weissfeld; Janet M Catov; Francesmary Modugno; Clareann H Bunker; Roberta B Ness; Brenda Diergaarde Journal: J Clin Oncol Date: 2014-11-17 Impact factor: 44.544
Authors: Ann C Mertens; Jian Yong; Andrew C Dietz; Erin Kreiter; Yutaka Yasui; Archie Bleyer; Gregory T Armstrong; Leslie L Robison; Karen Wasilewski-Masker Journal: Cancer Date: 2014-12-29 Impact factor: 6.860
Authors: M L G Janssen-Heijnen; F N van Erning; D K De Ruysscher; J W W Coebergh; H J M Groen Journal: Ann Oncol Date: 2015-02-11 Impact factor: 32.976
Authors: Peter M de Blank; Quinn T Ostrom; Chaturia Rouse; Yingli Wolinsky; Carol Kruchko; Joanne Salcido; Jill S Barnholtz-Sloan Journal: Cancer Med Date: 2015-01-27 Impact factor: 4.452
Authors: Mieke Van Hemelrijck; Yasin Folkvaljon; Jan Adolfsson; Olof Akre; Lars Holmberg; Hans Garmo; Pär Stattin Journal: BJU Int Date: 2015-05-15 Impact factor: 5.588
Authors: J Brian Szender; Tiffany Emmons; Sarah Belliotti; Danielle Dickson; Aalia Khan; Kayla Morrell; A N M Nazmul Khan; Kelly L Singel; Paul C Mayor; Kirsten B Moysich; Kunle Odunsi; Brahm H Segal; Kevin H Eng Journal: Gynecol Oncol Date: 2017-06-16 Impact factor: 5.482
Authors: Arun Kanakkanthara; Larry M Karnitz; Thomas L Ekstrom; Nicholas M Pathoulas; Amelia M Huehls Journal: Mol Cancer Ther Date: 2021-06-17 Impact factor: 6.261
Authors: Dylan M Glubb; Sharon E Johnatty; Michael C J Quinn; Tracy A O'Mara; Jonathan P Tyrer; Bo Gao; Peter A Fasching; Matthias W Beckmann; Diether Lambrechts; Ignace Vergote; Digna R Velez Edwards; Alicia Beeghly-Fadiel; Javier Benitez; Maria J Garcia; Marc T Goodman; Pamela J Thompson; Thilo Dörk; Matthias Dürst; Francesmary Modungo; Kirsten Moysich; Florian Heitz; Andreas du Bois; Jacobus Pfisterer; Peter Hillemanns; Beth Y Karlan; Jenny Lester; Ellen L Goode; Julie M Cunningham; Stacey J Winham; Melissa C Larson; Bryan M McCauley; Susanne Krüger Kjær; Allan Jensen; Joellen M Schildkraut; Andrew Berchuck; Daniel W Cramer; Kathryn L Terry; Helga B Salvesen; Line Bjorge; Penny M Webb; Peter Grant; Tanja Pejovic; Melissa Moffitt; Claus K Hogdall; Estrid Hogdall; James Paul; Rosalind Glasspool; Marcus Bernardini; Alicia Tone; David Huntsman; Michelle Woo; Aocs Group; Anna deFazio; Catherine J Kennedy; Paul D P Pharoah; Stuart MacGregor; Georgia Chenevix-Trench Journal: Oncotarget Date: 2017-06-15